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We present a novel highly efﬁcient protocol to magnetically labelT cells applying electrosta-
tically stabilized very small superparamagnetic iron oxide particles (VSOP). Our long-term
aim is to use magnetic resonance imaging (MRI) to investigate T cell dynamics in vivo
during the course of neuroinﬂammatory disorders such as experimental autoimmune
encephalomyelitis (EAE), an animal model of multiple sclerosis. Encephalitogenic T cells
were co-incubated with VSOP, or with protamine-complexedVSOP (VProt), respectively, at
different conditions, optimizing concentrations and incubation times. Labeling efﬁcacy was
determined by atomic absorption spectrometry as well as histologically, and evaluated on
a 7T MR system. Furthermore, we investigated possible alterations of T cell physiology
caused by the labeling procedure. T cell co-incubation with VSOP resulted in an efﬁcient
cellular iron uptake. T2 times of labeled cells dropped signiﬁcantly, resulting in prominent
hypointensity on T2∗-weighted scans. Optimal labeling efﬁcacy was achieved by VProt
(1mM Fe/ml, 8 h incubation; T2 time shortening of ∼80% compared to untreated cells).
Although VSOP promoted T cell proliferation and altered the ratio of T cell subpopulations
toward a CD4+ phenotype, no effects on CD4 T cell proliferation or phenotypic stability
were observed by labeling in vitro differentiatedTh17 cells with VProt.Yet, high concentra-
tions of intracellular iron oxide might induce alterations in T cell function, which should be
considered in cell tagging studies. Moreover, we demonstrated that labeling of encephal-
itogenic T cells did not affect pathogenicity; labeled T cells were still capable of inducing
EAE in susceptible recipient mice.
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INTRODUCTION
T cells are key players in inﬂammatory and degenerative disorders
of the central nervous system (CNS), including frequent illnesses
such as Alzheimer’s disease (Weiner and Frenkel, 2006) or stroke
(Hendrix and Nitsch, 2007), apart from their well described impli-
cation in infectious and autoimmunediseases. Inmultiple sclerosis
(MS), encephalitogenic T cells are suspected to trigger demyeli-
nation and neuronal damage resulting in persisting disability in
patients (Zipp and Aktas, 2006). T cells were shown to directly
induce neuronal cell death in murine brain slices (Aktas et al.,
2005). In order to gain further insight into the pathogenesis of
T cell mediated diseases, a sensitive method to monitor lympho-
cyte trafﬁcking in vivo would be of utmost interest. Novel imaging
methods visualizing cells have recently emerged or undergone
reﬁnement. Among these,magnetic resonance imaging (MRI) has
held its ground as an elaborate in vivo tool to non-invasively
observe temporal and spatial migration of labeled cells (Modo
et al., 2005; Arbab et al., 2006; Liu and Frank, 2008). A prereq-
uisite for MR cell tracking is the efﬁcient labeling of cells by
a contrast agent that is able to evoke a high cell-to-tissue con-
trast. For this purpose, magnetic nanoparticles have become well
appreciated. Magnetic particles cause strong susceptibility effects
on T2- and T2∗-weighted sequences, and are generally well toler-
ated by labeled cells and the organisms under investigation (Rogers
et al., 2006). However, in contrast to phagocytic cells such as
macrophages, that are easily labeled in vitro and in vivo due to
their natural disposition to internalize particles, tagging of T lym-
phocytes has remained a particular challenge. Only few studies to
data have achieved successful T cell labeling in vivo (Yeh et al.,
1995; Dodd et al., 2001; Kircher et al., 2003; Anderson et al., 2004;
Pirko et al., 2004; Billotey et al., 2005;Daldrup-Link et al., 2005;Hu
et al., 2005; Smirnov et al., 2008). So far, the reluctance of T cells to
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incorporatemagnetic nanoparticles has remained amajor obstacle
to MR investigations.
We here developed a novel T lymphocyte labeling proto-
col applying very small superparamagnetic iron oxide particles
(VSOP). In contrast to commonly used polymer-coated magnetic
nanoparticles, VSOP are extremely small, but inherit superior
labeling properties due to an electrostatically stabilized citrate
coating (Fleige et al., 2002). VSOP have already been success-
fully applied for the visualization of neuronal precursor cells
(Focke et al., 2008),mesenchymal stem cells (Heymer et al., 2008),
macrophages in a murine ischemia model (Stroh et al., 2005), as
well as macrophages and activated microglia in a mouse model of
MS (Wuerfel et al., 2007). Considering the limited phagocytic abil-
ity of T lymphocytes, we compared VSOP co-incubation with cell
transfection applying protamine-complexed VSOP (VProt). Pro-
tamine is a naturally occurring peptide with membrane translo-
cating properties (Reynolds et al., 2005); it is FDA approved as a
routine antidote to heparin-induced blood anticoagulation. In the
past, no modiﬁcation of cell viability, proliferation, or differentia-
tion has been noted when protamine was applied as a transfection
agent (Arbab et al., 2004, 2005; Suzuki et al., 2007). Our protocol
has been established on freshly isolated encephalitogenic murine
T cells, which are commonly used to induce experimental autoim-
mune encephalomyelitis (EAE), via adoptive transfer (Wuerfel
et al., 2007). The study was speciﬁcally designed to investigate
the potential impact of the labeling procedure on T cell function-
ality as well as to optimize the labeling efﬁcacy for future transfer
EAE in vivo experiments.
MATERIALS AND METHODS
MAGNETIC NANOPARTICLES FOR CELL LABELING
We applied VSOP (VSOP-C200, Ferropharm GmbH, Teltow, Ger-
many) for T cell labeling with magnetic nanoparticles. VSOP
are electrostatically stabilized nanoparticles coated with citrate
monomers comprising a hydrodynamic diameter of 7.6± 2.1 nm
and yielding a negative surface charge with a zeta potential of
−45.6± 30.7mV.
For the preparation of VProt, VSOP were decorated with pro-
tamine (protamine from salmon, Sigma-Aldrich, Munich, Ger-
many) by non-covalent electrostatic attraction. Protamine, a pep-
tide of about 32 amino acids, is positively charged due to 22
arginines. The positive surface charge of VProt keeps the particles
in suspension.VSOP (25ml; 6.6mMFe,pH7.4)was rapidlymixed
with 25ml protamine (0.5mM,pH7.4). Thereafter,VProtwas dia-
lyzed for 24 h in a Spectra/Por-7 membrane against water (molec-
ular weight cut-off 15000, SpectrumLaboratories, Eindhoven,The
Netherlands). The hydrodynamic diameter and the zeta potential
of VProt were determined by measuring dynamic light scattering
with a Zetasizer nano ZS (Malvern Instruments, Worcestershire,
UK) in water according to the manufacturers instructions. Com-
pared to the parent material VSOP, the hydrodynamic size was
substantially increased to 42 ± 16 nm and the surface charge was
reversed (zeta potential+57.9± 6.78mV).The iron concentration
was determined spectrophotometrically (Shen et al., 1993).
CELL CULTURE AND LABELING
T cells were obtained from 6- to 8-week-old female SJL
mice (Charles River, Sulzfeld, Germany), housed in a pathogen
free-environment. All experiments were approved by the by the
local animal welfare committee (LAGeSo Berlin, Germany), and
conformed to the European Communities Council Directive
(86/609/EEC). Mice were immunized subcutaneously with 200μg
PLP 139–1051 (Pepceuticals, Leicester, UK), 600 μg Mycobac-
terium tuberculosis H37Ra (Difco Laboratories Detroit,MI,USA)
emulsiﬁed in 100 μl Complete Freund’s adjuvant (CFA, Difco
Laboratories Detroit, MI, USA) and 100 μl phosphate buffered
saline (PBS). Mice were sacriﬁced 10 days after immunization,
and paraaortal, popliteal as well as inguinal lymph nodes were
extracted. For cell isolation, tissue was macerated through an
80-μm mesh (BD Falcon, Heidelberg, Germany). Lymph node
cells were re-stimulated for 4 days with 12.5 μg PLP in RPMI
1640 cell culture medium (Sigma-Aldrich, Munich, Germany)
supplemented with 10% fetal calf serum, 1% glutamine, 1%
penicillin/streptomycin, and 1% Hepes buffer at 37˚C. There-
after, the fraction of CD3+ T cells was enriched (purity 90–
95%) using a negative magnetic selection kit for T cells (Dynal
Invitrogen, Oslo, Norway). Subsequently, T cells were plated
at a concentration of 2× 106 cells/ml in cell culture medium
with 100U/ml IL-2 (Invitrogen, Karlsruhe, Germany) and left
for 1 h at 37˚C to recover. Optimal settings for cell labeling by
co-incubation with VSOP were determined varying the incu-
bation time (1 h, 4 h, 8 h, 12 h, 24 h, 2 days, 4 days) as well as
the concentrations (0.5, 1, 3, 6, 9mM Fe/ml), based on proto-
cols previously approved for macrophage labeling (Fleige et al.,
2002). Equivalent dose ﬁnding experiments were carried out
applying VProt (0.001, 0.01, 0.05, 0.1, 1, 3mM Fe/ml). After
co-incubation, cells were thoroughly washed three times with
PBS to remove excessive contrast agent. Cell viability was deter-
mined in a trypan-blue exclusion assay using a Neubauer counting
chamber.
ASSESSMENT OF IRON UPTAKE
Intracellular iron uptake was assessed by atomic absorption spec-
troscopy (AAS). For cell lysis, 6 × 105 cells were incubated with
50μl HCl 32% until complete dissolution and then topped up
to 3ml with distilled water. Samples could subsequently be mea-
sured by an atom absorption spectrometer (Unicam 969; Nicolet
Instruments GmbH, Offenbach, Germany).
Additionally, nuclear magnetic resonance (NMR) transverse
relaxation time (T2)was determined by relaxometry (BrukerMin-
ispec MQ 40, 0.94 T,Karlsruhe,Germany), as previously described
(Stroh et al., 2004, 2006). A suspension of 2× 106 cells in 1ml
cell culture medium supplemented with 5% fetal calf serum,
1% penicillin/streptomycin, and 1% Hepes buffer, was preheated
to 40˚C before measurement to avoid temperature equilibration
artifacts.
In all in vitro MRI experiments, labeled and thoroughly washed
T cellswere resuspended in preheated 1%agarose in distilledwater,
and transferred to 500μl tubes, which we embedded in agarose-
preﬁlled 50ml tubes. These gel phantoms were subsequently
imaged applying a T2∗-weighted sequence (GEFI, TR 1200ms, TE
5.6ms, 6 slices, 1mm slice thickness, matrix 4× 3.06 cm) on a 7 T
small animalMRI Scanner (Pharmascan 70/16AS,Bruker BioSpin,
Ettlingen, Germany). We included control samples of unsorted
lymph node cells in all measurements to exclude a contamination
of magnetic beads deriving from the cell separation kit.
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Formicroscopy,cellswere incubatedonPoly-d-Lysine (BDBio-
sciences,Heidelberg,Germany) coated object slides for 2 h,washed
three times with PBS, and ﬁxed for 10min in 4% paraformalde-
hyde in PBS. Prussian Blue staining was performed on the slides
according to Pearl’s method (Perl and Good, 1992) for visual-
ization of the iron oxide particles. Cells were examined by epi-
ﬂuorescence microscopy and digitally photographed (Olympus
BX-51,Hamburg, Germany). Images were assembled using Adobe
Photoshop (Adobe Systems, San Jose, CA, USA).
3[H]THYMIDINE INCORPORATION ASSAY
Antigen-speciﬁc proliferation was assessed by a 3[H]thymidine
incorporation assay. Brieﬂy, PLP-primed CD3+-enriched T cells
were incubated with irradiated splenocytes in cell culture medium
in a 96-well plate (BD Falcon, Heidelberg, Germany) at concen-
trations of 50000 T cells and 150000 splenocytes per well. Prolifer-
ation was induced by 12.5 or 25μg PLP added to the medium and
compared to the untreated condition. Each conditionwas repeated
with different VSOP concentrations (1, 3, 6, 9mM Fe/ml). After
48 h, 0.5μCi 3[H]thymidine (Amersham, Buckinghamshire, UK)
was added to the culture, and the incorporation into the T cell
DNA measured with a beta counter (Wallac, Freiburg, Germany)
18 h later.
FLOW CYTOMETRY
Cell death, activation as well as differentiation markers were inves-
tigated by ﬂow cytometric analysis. After the labeling procedure,
T cells were incubated with CD16/CD32 to avoid unspeciﬁc anti-
body binding and stained afterward with anti-CD3-FITC, anti-
CD4-PE and anti-CD8-FITCantibodies.After staining, all samples
were thoroughly washed, and analyzed by ﬂow cytometry (FAC-
SCalibur,BDBiosciences,Heidelberg,Germany). Cell viabilitywas
determined by adding 0.1mg propidium iodide/ml to the sample
immediately before acquisition.
GENERATION AND ASSESSMENT OF PROLIFERATION AND CYTOKINE
PRODUCTION OF DIFFERENTIATED IL-17 PRODUCING T CELLS
Spleen and lymph nodes were collected from TCR transgenic
mice (2D2) speciﬁc for MOG 35–55, and a CD4 naive MACS
separation was performed to generate Th17-polarized T cells.
T cells were co-cultured in a 1:4 ratio with CD90-depleted, irra-
diated antigen presenting cells, taken from wild-type C57Bl/6
mice in the presence of TGF-β (3 ng/ml), IL-23 (20 ng/ml), and
IL-6 (20 ng/ml) all from R&D. IL-2 was added to the cultures
at day 3. After 7 days, the T cells were re-stimulated for 72 h
at 37˚C in 5% CO2 with cytokines in the presence of Vprot
(0.3 or 1mM) or an equivalent amount of protamine alone
and carboxyﬂuorescein succinimidyl ester (CFSE, 2.5μM) to
assess proliferation. Subsequently, the cells were stained with
anti-CD4 antibodies (BD, Heidelberg, Germany). Additionally, to
monitor phenotypic stability, a cell fraction was ﬁxed with 2%
formaldehyde for 20min and then permeabilized with saponin
(0.5%; Sigma) for intracellular staining with anti-IL-17 antibod-
ies (eBioscience, Frankfurt, Germany) as described previously
(Infante-Duarte et al., 2000). The proportion of proliferating
CD4-positive cells and IL-17-producing cells was analyzed by ﬂow
cytometry.
ADOPTIVE TRANSFER EAE
For adoptive transfer EAE, PLP-speciﬁc T cells obtained from
PLP immunized mice were cultured in the presence of VSOP
or VProt for 4 days as described in 2.2. To induce EAE, 8–
12× 106 T-cell blasts in 100μl PBS were injected intraperi-
toneally into syngenic recipients (Wuerfel et al., 2010). Mice were
weighed daily and scored for neurological deﬁcits as previously
described (Wuerfel et al., 2010): 0, unaffected; 1, tail weakness or
impaired righting reﬂex; 2, paraparesis; 3, paraplegia; 4, paraple-
gia with forelimb weakness or complete paralysis; score >3, to be
sacriﬁced.
DATA ANALYSIS
Oneway/univariateANOVAwith post hoc Scheffé analysis was per-
formed to determine signiﬁcant differences (p< 0.05) between
VSOP, VProt and negative controls. AAS measurements were run
in triplicate. The relaxometry data presented in this study were
pooled from three different experiments, each run in duplicate,
except for the time course experiment in Figure 2C, which was
conducted only once in duplicate, and hence excluded from fur-
ther statistical analysis. Flow cytometry data were obtained from
four independent experiments. The proliferation assay was con-
ducted in quadruplicate. Data in the ﬁgures present mean values
and standard deviation.
RESULTS
T CELL LABELING BY CO-INCUBATION WITH VSOP
First we determined the optimal concentration of VSOP and the
best incubation time for labeling T cells. Efﬁcient T cell label-
ing was achieved after 24 h co-incubation with VSOP at con-
centrations approved for macrophage labeling (1–9mM Fe/ml)
as reﬂected by Prussian Blue staining in Figure 1A. The vesicu-
larly shaped distribution of particles suggested an accumulation
within cytosolic endosomes. The amount of intracellular VSOP
augmented with increasing concentrations of VSOP during co-
incubation (Figure 1A1–3). However, at concentrations exceeding
6mM Fe/ml, unspeciﬁc adherence of VSOP to the cellular surface
became more prominent (Figure 1A3).
Relaxometry measurements revealed a sequential shortening
of T2 times by increasing VSOP concentrations during incu-
bation. We observed a decrease of T2 times from 832.4ms at
1mM Fe/ml to 329.7ms at 9mM Fe/ml (Figure 1B). The ANOVA
group difference between VSOP treated and unlabeled control
cells was signiﬁcant (p< 0.001). Post hoc Scheffé testing revealed
a signiﬁcant difference already at lowest VSOP concentrations at
1mM Fe/ml VSOP (p< 0.001). Accordingly, the iron content per
T cell determined by atomic absorption spectrometry increased
with augmenting VSOP labeling concentrations between 1 and
9mM Fe/ml. After 24 h of co-incubation, maximal uptake was
reached for 9mM Fe/mlVSOP, resulting in 34.92 pg iron per T cell
(Table 1A). T cell phantoms were imaged on a 7 T rodent scanner.
At a concentration of 1000 cells/μl agarose, T cells were clearly
distinguishable as hypointense spots on T2∗-weighted images
(Figure 1C).
Applying a moderate concentration of 3mM Fe/ml during the
labeling procedure, we assessed the time dependency of VSOP
uptake. The amount of iron per T cell increased with the extension
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of incubation time, reaching a maximal concentration of 10.12 pg
Fe/cell after 48 h (Table 1B).
IMPROVED T CELL LABELING CAPACITY OF VProt
Considering the limited phagocytic ability of T lymphocytes, we
compared VSOP co-incubation with cell transfection applying
protamine-complexed VProt. Protamine is a naturally occurring
peptide with membrane translocating properties (Reynolds et al.,
FIGURE 1 |T cell labeling efficiency and magnetic nanoparticle
distribution was evaluated microscopically by Prussian Blue staining.
Higher labeling concentrations resulted in an augmentation of incorporated
VSOP into cytoplasmatic endosomes [(A1), 3mM Fe/ml; (A2), 6mM Fe/ml;
(A3), 9mM Fe/ml]. At a concentration of 9mM Fe/ml, VSOP aggregated
and non-speciﬁc adherence to the cell surface occurred (A3). We assessed
NMR transverse relaxation times (T2) as a measure of theT cell labeling
efﬁcacy by relaxometry (B). T2 times decreased signiﬁcantly (p<0.001) and
in a concentration-dependent manner after incubation of T cells with VSOP
for 20 h. Agarose phantoms containing labeledT cells at a concentration of
1000 cells/μl, imaged at 7T, are presented at different labeling
concentrations (ut, untreated; 1–9mM Fe/ml) into (C).
2005). We investigated whether complexation of VProt prior to
the actual labeling procedure would improve the uptake of mag-
netic nanoparticles into the cells. Incubation of T cells with VProt
resulted in signiﬁcantly reduced incubation times and labeling
concentrations for efﬁcient labeling. In histology, Prussian Blue
stained T cells incubated with VProt were more homogenously
labeled (Figure 2A) compared to cells incubatedwith simpleVSOP
(Figure 1A). The distribution seemed less scattered within the
cells but uniformly spread throughout the cytoplasm, potentially
due to an additional uptake mechanism independent from the
accumulation in endosomes. Labeling was visibly increased by
prolongation of the incubation times (Figure 2A1–3). However,
after 12 h of labeling, VProt also aggregated to the cell surface
(Figure 2A3). Sufﬁcient labeling was feasible at concentrations as
low as 0.5mMFe/ml at incubation times of 12 h. T2 times dropped
to 125.2ms applying 1mM Fe/ml VProt, considerably exceed-
ing the T2 shortening achieved by VSOP (Figure 2B; p< 0.001,
ANOVA). Investigating the kinetics of VProt and VSOP uptake,
we applied a moderate concentration of 1mM Fe/ml for both
contrast agents. In T cells, VSOP incorporation increased steadily
with time. In contrast, VProt-incubated T cells achieved high T2
time reductions even in the early phase. After 8 h of incubation,
T2 time reduction reached a peak, widely exceeding the levels of
VSOP treated cells (Figure 2C). Imaging of VProt labeled cells
suspended in agarose using a 7 T rodent scanner conﬁrmed the
high labeling efﬁcacy detected by microscopy. Compared to bare
VSOP, T cells incubated with VProt at concentrations as low as
0.5–1mM Fe/ml caused a strong hypointensity on T2∗-weighted
images (Figure 2D).
EFFECTS OF VSOP AND VProt ON THE VIABILITY OF
ENCEPHALITOGENIC T CELLS
Incubation with VSOP did not suppress T cell proliferation
measured by a 3[H]thymidine assay. VSOP-labeled CD3+ cells
showed increased proliferation rates in the presence of speciﬁc
antigen (PLP), equivalent to control cells, in a concentration-
dependent manner (Figure 3). Scheffé testing indicated a signiﬁ-
cantly increasedproliferation capacity at lowVSOPconcentrations
(1mM Fe/ml) compared to untreated cells (p< 0.01), but not at
Table 1 | Iron uptake intoT cells after simple incubation withVSOP quantified with atomic absorption spectroscopy in probes containing
600000 cells.
Incubation time (h) Concentration (mM) Fe in probe in μg mean±SD Calculated Fe per cell in pg
A 24 untreated 0.365±0.027 0.61
24 1 4.904±0.101 8.17
24 3 10.404±0.115 17.34
24 6 15.582±0.028 25.97
24 9 20.949±0.632 34.92
B 48 untreated 0.21±0.014 0.35
2 3 4.107±0.068 6.85
6 3 4.576±0.206 7.63
12 3 4.762±0.135 7.94
24 3 5.169±0.241 8.62
48 3 6.070±0.015 10.12
SD, standard deviation.
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FIGURE 2 | InT cells, diffusely distributed intracellular magnetic
nanoparticles are present after labeling with 1mM Fe/mlVProt for 1h
(A1), 4 h (A2), and 10h (A3). NMR transverse relaxation time (T2) after
T cell labeling was estimated by relaxometry. Comparing the labeling
efﬁcacy of VSOP to that of protamine-complexed VSOP (VProt), we found
that after 10 h of incubation, T2 times were signiﬁcantly reduced (p<0.001)
in VProt samples already at low concentrations (B). In a longitudinal
experiment we noted a continuous reduction of T2 times at a concentration
of 1mM Fe/ml over 21 h in VSOP-labeledT cells. In contrast, VProt labeled
T cells reached a maximum already after 8 h of incubation (C). In agarose
phantoms containingT cells at a concentration of 1000 cells/μl, imaged on a
7T scanner, hypointensities caused by VProt labeled cells in T2∗-weighted
images were more homogenously distributed and produced pronounced
signal extinctions even at low labeling concentrations (0.5–1mM Fe/ml)
compared to VSOP-labeledT cells (D). UntreatedT cells (ut) caused only
discrete signal hypointensities.
higher VSOP concentrations (3–9mM Fe/ml). The viability of
T cells after 24 h incubation at different concentrations (1–9mM
Fe/ml VSOP) determined by propidium iodide incorporation in
ﬂow cytometry was not signiﬁcantly impaired (Figure 4A). We
assessed potential effects of VSOP on T cell differentiation ana-
lyzing CD4+ and CD8+ T cell subpopulations. The proportion of
CD4+ T cells appeared slightly increased, while the proportion of
CD8+ T cells was decreased at high VSOP co-incubation concen-
trations (Figure 4B), although this effect did not reach statistical
signiﬁcance. Subsequent propidium iodide staining revealed that
a signiﬁcant shift was caused by selective induction of cell death
in the CD8+ T cell population labeled with VSOP compared to
untreated T cells (Figure 4C; p< 0.05). In CD4+ T cells, only
the highest VSOP concentration (9mM Fe/ml) reduced viability
(p< 0.05).
FIGURE 3 | Changes in the proliferative capacity ofT cells were
assessed in a 3[H]thymidine assay.T cells incubated with VSOP
concentrations of 1–9mM Fe/ml were compared to unlabeled cells (ut).
Proliferation rates were determined in the presence of the speciﬁc antigen
proteolipid protein (PLP) in two concentrations (12.5 and 25μg/ml) and
without stimulation. After incubation with low VSOP concentrations
(1–3mM Fe/ml), the proliferation rate was signiﬁcantly increased compared
to untreated cells (p =0.003).
EFFECTS OF VProt ON THE PHENOTYPE OF DIFFERENTIATED TH17
ENCEPHALITOGENIC T CELLS
The relative effects ofVSOP (1 mM)onPLP-speciﬁcT cell prolifer-
ation, as described above,may also result from a more pronounced
induction of apoptosis in CD8 positive cells, that could be detected
at equivalent VSOP concentrations. Therefore, we established a
simpliﬁed system using TCR transgenic CD4 T cells (our target
cells), to monitor the effects of VSOP, and in particular VProt,
on CD4 T cell physiology. In these experiments, we also com-
pared protamine alone versus VProt, affecting antigen-speciﬁc
proliferation and cytokine production.
Hence, MOG-speciﬁc 2D2-TCR transgenic CD4 T cells were
differentiated in vitro under Th17-polarizing conditions. VProt at
0.3 and 1mM, or equivalent concentrations of protamine, respec-
tively, were added to the cell culture medium at day 7, the time
point of restimulation. Proliferationof 2D2-TCR transgenicT cells
in the presence of the speciﬁc antigen MOG was assessed by CFSE
dilution assays and monitored by ﬂow cytometry. The effect of
VProt or protamine alone on phenotype proﬁle, as deﬁned by the
production of IL-17, was determined by intracellular staining of
IL-17 in CD4 T cells.
CFSE based dilution assays showed that neitherVProt nor prot-
amine alone affected theproliferationof MOG-speciﬁcCD4Tcells
in vitro at the applied concentrations (Figure 5A).
Furthermore, the amount of CD4 cells expressing IL-17 or
the production of IL-17 was not inﬂuenced by the addition of
VProt or protamine alone (Figure 5B, representative ﬂow cytom-
etry proﬁles are given in Figure 5C). About 30% of CD4 T cells
differentiated into Th17 T cells under both conditions.
ADOPTIVE TRANSFER EAE BY ENCEPHALITOGENIC VSOP-CD4 T CELLS
In order to demonstrate the encephalitogenic potential of labeled
T cells, we performed a murine adoptive transfer SJL-EAE with
PLP-speciﬁc T cells obtained from PLP immunized mice, which
were subsequently labeled in vitro with VSOP or VProt. Five out
of seven recipient mice transferred with VSOP-T cells developed
EAE with a median onset at day 10 after immunization (range
www.frontiersin.org December 2011 | Volume 2 | Article 72 | 5
Wuerfel et al. T cell labeling for MRI
FIGURE 4 |We investigated the influence ofVSOP onT cell viability,
differentiation and activation.The number of dead cells was quantiﬁed by
FACS analysis using propidium iodide (PI). No signiﬁcant reduction of cell
viability was detected using VSOP concentrations of 1–9mM Fe/ml in
comparison to untreated cells (ut) (A). The percentage of CD4+ cells within
the CD3+ T cell pool was augmented by increasing VSOP concentrations,
while the percentage of CD8+ cells diminished slightly, although without
reaching statistical signiﬁcance (B). With increasing VSOP concentrations, we
noted an increasing number of PI positive cells in the CD8+ cell pool
indicating cell death (C).
6–12) and maximum disease severity ranging from score 1 to 4
(Figure 6). As proof of principle, two recipient mice were trans-
ferred withVProt labeled T cells, and both of these mice developed
EAE,presenting ﬁrst signs of disability at day 9 and 10, respectively,
after transfer.
Thus, in vitro labeled PLP-speciﬁc T cells were capable of
inducing EAE.
DISCUSSION
The motivation for this study was the development of a lympho-
cyte labeling technique suited for longitudinal visualization and
tracing of encephalitogenic T cells within the CNS during the
induction and the course of EAE in vivo by MRI. Recently, success-
ful labeling and in vivo tracking of lymphocytes have been shown
in different tumormodels (Kircher et al., 2003;Daldrup-Link et al.,
2005; Hu et al., 2005) and a model of autoimmune diabetes (Bil-
lotey et al., 2005). To our knowledge, imaging of T cellmigration to
the CNS has been reported only twice up to now (Anderson et al.,
2004; Pirko et al., 2004), and both studies were hampered by rel-
atively low resolution and difﬁculties to assign hypointensities in
T2∗-weighted images to labeled cells, as distinct fromblood vessels
or other confounders. Thus the need to improve T cell labeling for
subsequent use in in vivo studies during EAE is obvious. This rep-
resents a particular challenge because of the time gap of 8–12 days
between T cell transfer and disease onset (Wuerfel et al., 2007)
and the consequent T cell divisions and dilution of the nanopar-
ticles, that takes place during this time interval in the recipient
mice. An additional difﬁculty is that only a very low fraction of
the initially transferred T cells inﬁltrate into the CNS (Raine et al.,
1990). Externalized nanoparticles, e.g., released fromdying labeled
T2 cells, will eventually be internalized by local macrophages or
activated microglia, as shown in previous murine (Wuerfel et al.,
2007) as well as human (Vellinga et al., 2008) studies, or adhere to
the perivascular extracellular matrix (Wuerfel et al., 2007).
We applied electrostatically stabilized very small particles,
VSOP, since these nanoparticles showed excellent labeling proper-
ties, achieving a 5.7-fold higher labeling efﬁcacy of macrophages
compared to conventional dextran-coated magnetic nanoparti-
cles, as demonstrated in a previous study (Fleige et al., 2002). In our
hands, incubation of freshly isolated T lymphocytes with VSOP in
a concentration of 3mM Fe/ml over 24 h was well tolerated, and
resulted in an iron uptake of 17.37 pg per cell, well above the level
of 1–5 pg of iron per cell achieved with commonly used protocols
(Arbab et al., 2006), and corresponding to a 55% shortening of
the T2 time, as compared to unlabeled control cells. The uptake of
VSOP was dependent on the concentration as well as on the incu-
bation time applied, and could thus be slightly increased using
higher VSOP dosages or extending the incubation period.
A commonly used method to further enhance labeling efﬁ-
cacy relies on the use of secondary compounds with transfection
agents (Walczak et al., 2005). Among various approaches includ-
ing viral transactivator transcription proteins (Lewin et al., 2000;
Dodd et al., 2001; Kircher et al., 2003), polycationic transfection
agents (Frank et al., 2003; Berger et al., 2006), or electroporation
(Daldrup-Link et al., 2005; Suzuki et al., 2007), protamine has
recently been employed by several groups. Delivering high cell
transfection efﬁcacy, this compound confers only very low toxic-
ity in comparison to other transfection agents (Arbab et al., 2004;
Reynolds et al., 2005; Anderson et al., 2006). We did not detect
any inﬂuence of VProt on T cell viability and activation (data not
shown), conﬁrming other studies that excluded inﬂuences of pro-
tamine on cell viability, proliferation, and stem cell differentiation
(Arbab et al., 2004, 2005; Suzuki et al., 2007).
We show here that the complexation of protamine to VSOP
boosted the uptake of nanoparticles into T cells, and allowed for a
reduction of VSOP dosage as well as of incubation times. In com-
parison to VSOP only, T2 relaxation times were reduced by 62%
after 12 h of incubation with a concentration of 0.5mM Fe/ml
VProt. MR images of T cell phantoms conﬁrmed the high label-
ing efﬁcacy of VProt. VProt uptake reached a maximum after 8 h
of incubating T cells with 1mM Fe/ml, potentially resulting from
different cellular uptake mechanisms of VSOP compared toVProt.
Intracellular storage of VProt appeared diffuse in light microscopy
differing from the vesicular distribution evident in T cells incu-
bated with VSOP. Fleige et al. (2002) showed that macrophages
internalizeVSOP via phagocytosis. In contrast, polycationic trans-
fection agents promote ingestion by macropinocytosis (Arbab
et al., 2006). Whether these pathways also apply to the entry of
VSOP and VProt into lymphocytes remains to be determined.
Recent reports stress the importance of the surface charge and the
size of magnetic nanoparticles as being crucial for the uptake into
non-phagocytic cells (Thorek and Tsourkas, 2008). Accordingly,
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FIGURE 5 | Effects ofVProt onTh17 proliferation and cytokine
production. (A) Incubation of Th17 cells for 3 days with VProt or protamine
alone had no effect onTh17 proliferation, given as the percentage of cells
showing one or more cell divisions, gated on CD4-positive cells. (B)
Incubation of Th17 cells with VProt or protamine alone did not affect IL-17
production, shown as the percent of CD4-positive cells which were
IL-17-positive. Percentages reﬂect anti-CD3/anti-CD28-stimulated cells after
subtraction of baseline values from non-stimulated cells. (C)
Representative ﬂow cytometry plots showing the uncorrected percentage
of IL-17-producing CD4-positive cells. n.s. not signiﬁcant compared to
control, by one-way ANOVA with Dunnet’s post hoc test.
the improved labeling efﬁcacy of VProt might thus result from a
larger diameter and positive zeta potential of VProt compared to
the negatively charged VSOP.
FIGURE 6 |VSOP-labeled cells are able to induce EAE. PLP-speciﬁc
T cells labeled with VSOP induced EAE in ﬁve out of seven SJL mouse
recipients. Graph shows mean clinical score, ±SEM.
In summary, balancing results from the different labeling con-
ditions, an incubation time of 8 h with a VProt concentration of
1mM Fe/ml can be recommended for subsequent in vivo stud-
ies, combining high labeling with minimal unspeciﬁc extracellular
binding.
We were particularly interested to rule out potential alterations
of the immunological T cell proﬁle as a prerequisite for future
EAE trials. However, we noted an increased proliferation capacity
of T lymphocytes after incubation with a VSOP concentration of
1mM Fe/ml. Our ﬁndings are in line with studies showing that
moderate concentrations of iron have a growth-promoting effect
on lymphocytes whereas high iron concentrations may reduce cell
proliferation (Djeha and Brock, 1992). Yet, in our cultures, this
increased relative CD4+ T cell proliferation may be linked to the
selectively enhanced cell death of CD8+ T cells observed at the
same time. Since we were particularly interested in the immuno-
logical proﬁle of the encephalitogenic CD4+ cell subpopulation
labeled with protamine-complexed VSOP, we focused in the next
experiments on this system exclusively. IL-17 producing T cell
are regarded as key players in the development of autoimmune
demyelinating disease (Zepp et al., 2011). Therefore, we investi-
gated the effect of VProt on proliferation and phenotype stability
of TCR transgenic CD4 T cells speciﬁc for MOG35–55 that were
differentiated in vitro toward a Th17 phenotype. Our data indi-
cate that, using this simpliﬁed set-up, labeling of T cells withVProt
did not affect IL-17 expression in T cells, and did not inﬂuence the
proliferative capacities of the MOG-speciﬁc Th17 cells.
Furthermore, we aimed to prove that VSOP-labeled encephal-
itogenic T cells were able to induce EAE in recipient mice. We
showed that PLP-speciﬁc T cells labeled with VSOP or VProt suc-
cessfully inducedEAE.Thus,our results demonstrate that theT cell
labeling method described herein does not inhibit the encephal-
itogenic capacity, and highlights the potential of this method
performing future in vivo investigations.
In conclusion, in vivo studies on cell migration, e.g., in EAE,
require a high labeling efﬁcacy in order to facilitate tracking
of labeled cells during a longer period of time. Additionally,
the impact of T cell labeling on cell viability, functionality, or
pathophysiological potency are of utmost importancewhen study-
ing T cell behavior and their role in vivo. We optimized T cell
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labeling, applyingVSOP andVProt at different concentrations and
incubation times, comparing labeling efﬁcacy in vitro. Best results
were achieved with VProt at a concentration of 1mM Fe/ml and
an incubation time of 8 h. These conditions did not affect CD4
T cell physiology in terms of proliferative capacities or phenotypic
stability. Finally, we showed that labeled encephalitogenic T cells
T cellsmaintained their pathologic potential and are able to induce
EAE in recipient mice.
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